Search Results - "FETT, Werner"

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups by UNTCH, Michael, FASCHING, Peter A, STICKELER, Elmar, HARBECK, Nadia, HÖSS, Cornelia, KAHLERT, Steffen, BECK, Thomas, FETT, Werner, MEHTA, Keyur M, VON MINCKWITZ, Gunter, LOIBL, Sibylle, KONECNY, Gottfried E, HASMÜLLER, Stephan, LEBEAU, Annette, KREIENBERG, Rolf, CAMARA, Oumar, MÜLLER, Volkmar, DU BOIS, Andreas, KÜHN, Thorsten

“…To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human…”
Get full text

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials by von Minckwitz, Gunter, Untch, Michael, Nüesch, Eveline, Loibl, Sibylle, Kaufmann, Manfred, Kümmel, Sherko, Fasching, Peter A, Eiermann, Wolfgang, Blohmer, Jens-Uwe, Costa, Serban Dan, Mehta, Keyur, Hilfrich, Jörn, Jackisch, Christian, Gerber, Bernd, du Bois, Andreas, Huober, Jens, Hanusch, Claus, Konecny, Gottfried, Fett, Werner, Stickeler, Elmar, Harbeck, Nadia, Müller, Volkmar, Jüni, Peter

“…Pathological complete response (pCR) to neoadjuvant treatment correlates with outcome in breast cancer. We determined whether characteristics of neoadjuvant…”
Get full text

First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study by Müller, Volkmar, Ruhnke, Markus, Hoffmann, Oliver, Grafe, Andrea, Tomé, Oliver, Fett, Werner, Bruch, Harald-Robert, Sommer-Joos, Ann-Katrin, Schneeweiss, Andreas

“…The multicentre non-interventional AVANTI study assessed safety, effectiveness and patient-reported outcomes with approved first-line bevacizumab-containing…”
Get full text

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer by Huober, Jens, Fett, Werner, Nusch, Arnd, Neise, Michael, Schmidt, Marcus, Wischnik, Arthur, Gerhardt, Steffen, Goehler, Thomas, Lück, Hans-Joachim, Rost, Andreas

“…Pegylated liposomal doxorubicin (PLD) is active in metastatic breast cancer. This observational study evaluated the efficacy and safety of PLD in patients…”
Get full text

Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma by Loibl, Sibylle, Volz, Cristina, Mau, Christine, Blohmer, Jens-Uwe, Costa, Serban D., Eidtmann, Holger, Fasching, Peter A., Gerber, Bernd, Hanusch, Claus, Jackisch, Christian, Kümmel, Sherko, Huober, Jens, Denkert, Carsten, Hilfrich, Jörn, Konecny, Gottfried E., Fett, Werner, Stickeler, Elmar, Harbeck, Nadia, Mehta, Keyur M., Nekljudova, Valentina, von Minckwitz, Gunter, Untch, Michael

“…Invasive lobular carcinomas (ILC) show better clinical behaviour compared with other histological types, but significantly lower pathological complete response…”
Get full text

Karyotype in multiple myeloma and plasma cell leukaemia by Weh, H J, Gutensohn, K, Selbach, J, Kruse, R, Wacker-Backhaus, G, Seeger, D, Fiedler, W, Fett, W, Hossfeld, D K

“…Between October 1988 and October 1991, 104 patients with multiple myeloma and 6 with plasma cell leukaemia were studied cytogenetically. Abnormal karyotypes…”
Get more information

Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma by Peest, D, Leo, R, Bloche, S, Hein, R, Stannat-Kiessling, S, Tschechne, B, Fett, W, Harms, P, Hoffmann, L, Bartl, R

“…In vitro data have demonstrated autologous T-lymphocytes with anti-tumour activity in multiple myeloma (MM). Therefore a phase I/II trial was conducted to…”
Get more information